Leinfelden-Echterdingen, 19.10.2024
MVS Pharma:Taking Action to Address Amoxicillin Shortage in Germany
Leinfelden-Echterdingen, Germany – October 19, 2024 – MVS Pharma GmbH, a pioneering pharmaceutical start-up company headquartered in Baden-Württemberg, has made significant strides in addressing the ongoing Amoxicillin shortage in Germany. In his first public interview, CEO Rainer Proksch revealed the company’s proactive efforts to import the essential antibiotic from a manufacturer in India, ensuring compliance with EU standards and safety regulations.
Speaking with IPPEN.MEDIA, Proksch highlighted the company’s initiative to independently verify the quality and safety of the imported active ingredient. “We thought we were doing something good and helping,” said Proksch, explaining that MVS Pharma conducted rigorous testing through a European laboratory and assumed all associated costs. The company also performed additional checks at the production site in India, securing certificates that prove adherence to EU pharmaceutical standards.
MVS Pharma’s efforts to combat the Amoxicillin shortage by bringing the active ingredient to Germany were submitted to the Stuttgart Regional Council along with an application for a special permit to combat the shortage. Despite the urgency of the situation, the application was denied, a decision that has left the company both surprised and frustrated. “We were told we could start the official approval process, but that takes a very long time. But they could have spoken to us, after all, it is an emergency situation,” said Proksch, reflecting on the lack of cooperation during such a critical time for public health.
The CEO of MVS Pharma GmbH, Mr. Proksch further criticized the barriers imposed by regulatory authorities, stating that the company’s proposal could significantly ease the shortage, ensuring that patients have access to life-saving antibiotics. “Patient welfare is completely ignored here,” he added, questioning why bureaucratic obstacles are preventing swift resolution of a clear medical emergency.
Founded three years ago, MVS Pharma GmbH is dedicated to innovating solutions that prioritize people’s general health, patient safety, and supply security. The company remains committed to addressing the Amoxicillin shortage and continues to explore alternative routes to expedite approval.
About MVS Pharma GmbH
MVS Pharma GmbH is a forward-thinking pharmaceutical company based in Leinfelden-Echterdingen, Germany, with a branch in India. Founded in 2021, the company specializes in providing high-quality, safe, and effective pharmaceutical solutions to address critical health challenges. MVS Pharma is driven by its commitment to patient safety, transparency, and regulatory compliance.
MVS Pharma is a manufacturer, with its own team of professionals and experts in each field. And because the main goal of the company is the well-being of its customers, it makes sure to create all its products using only the best raw materials, free from heavy metals, pesticides, plastic, etc. In addition, MVS Pharma is also working on further clinical research into rose hips for a natural treatment of osteoarthritis and pure fish oil, purified from heavy metals, protected against oxidation, and packaged under 7 other steps, which will guarantee its high quality.
For media inquiries, please contact:
Mihaela Ahchieva
Head of Public Relations
MVS Pharma GmbH
mihaela.ahchieva@mvs-pharma.com
